TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
HHS announced an interim policy allowing specified compounding of six peptides under stated conditions while the FDA considers formal rulemaking. An oncologist writing in MedPage Today says the policy is not FDA approval and does not establish that the substances are safe or effective; he highlights limited human evidence and unanswered questions about BPC-157 and cancer-related pathways.
HHS announced an interim enforcement-discretion policy covering six peptides on October 28, allowing licensed pharmacies and physicians to compound them under specified conditions while the FDA considers formal rulemaking. In a November 10 MedPage Today commentary, oncologist Gilberto de Lima Lopes Jr. cautioned that the policy is not FDA approval and does not establish safety or effectiveness, even as it may widen access to substances whose clinical evidence remains limited.
The six substances named in the policy are BPC-157, MOTS-c, TB-500, KPV, Semax and Epitalon. HHS said it does not intend to take enforcement action against licensed pharmacies and physicians compounding them when specified conditions are met. The source report says those conditions include appropriately sourced ingredients, documentation of identity and purity, single-ingredient preparations, labeling, serious adverse-event reporting and patient-specific prescriptions.
The policy followed a July meeting of the FDA’s Pharmacy Compounding Advisory Committee. The committee voted eight to six, with one abstention, to recommend BPC-157 for the compounding list and endorsed five of the other six substances considered. FDA reviewers, however, found insufficient evidence in briefing documents to support adding any of the seven substances they reviewed. For BPC-157, reviewers could not establish effectiveness for ulcerative colitis; human safety data for several substances were absent or extremely limited, and reviewers cited product-characterization problems.
Lopes also points to a July 2025 incident at a Las Vegas conference, where two women became seriously ill after receiving injections containing experimental peptides and required ventilators. Both recovered. Nevada regulators later imposed $35,000 in fines on four parties, but investigators could not establish what caused the reactions or verify the injections’ precise contents because they could not obtain the products for testing. The incident illustrates an unresolved risk, not proof that a particular peptide caused the harm.
Access Before Clinical Evidence
The policy brings a practical distinction into focus: allowing certain compounding under stated conditions is not the same as showing that a substance works. As Lopes writes, identity, safety and benefit are separate questions. Ingredient documentation can help establish what is in a preparation; it cannot show that patients benefit. A prescription likewise does not prove that a treatment has a favorable benefit-risk balance, and adverse-event reports cannot substitute for prospective safety studies.
That matters to patients encountering peptide claims through wellness clinics, telehealth and social media. Some may interpret a clinician’s prescription or a regulated pharmacy’s involvement as evidence that a treatment has been tested and shown effective. The policy does not provide that assurance. At the same time, Lopes acknowledges that patients already obtain experimental substances from poorly regulated online suppliers, and says conditional compounding could address some product-quality risks.
The concern is not that peptides have no therapeutic potential. Lopes says many may have it. His point is that commercial interest can run ahead of clinical evidence, especially when substances are promoted for uses beyond those examined by regulators. The policy’s safeguards address some manufacturing and oversight issues, but they do not resolve the evidence gap.
Products Worth Considering
Withings Sleep Under-Mattress Sleep Tracking Pad
Therabody Theragun Mini 3rd Generation Massage Gun, Black
Garmin Forerunner 165 GPS Running Smartwatch, 43 mm, Whitestone
As an affiliate, we earn on qualifying purchases.
From Advisory Review to Interim Policy
The policy followed debate over whether the substances should be available for compounding. At its July meeting, the FDA advisory committee recommended BPC-157 for the compounding list by a narrow vote and supported five other substances considered. FDA staff reviewers took a more cautious position, citing insufficient evidence across the seven substances and specific gaps in effectiveness, human safety information and product characterization.
Lopes writes from his experience conducting oncology trials, including research that contributed to immunotherapies and targeted agents. He argues that clinical development can be slow and disappointing, but it helps distinguish a promising biological mechanism from a treatment that benefits patients. He supports making review more efficient rather than bypassing it.
He also stresses that evidence does not automatically transfer between uses. The FDA reviewed BPC-157 for ulcerative colitis, while commercial interest often concerns tendon injuries, exercise recovery and anti-aging. Different indications can involve different doses, routes and durations, so findings in one setting cannot establish safety or effectiveness in another.
Safety and Benefit Remain Unsettled
The policy does not establish whether any of the six peptides is safe or effective for a particular condition. The source report does not give a timeline for FDA rulemaking or specify how long the interim enforcement approach will remain in place. It is also unclear how many patients or pharmacies may use the pathway, and what monitoring data will emerge.
For BPC-157, experimental studies suggest activity involving angiogenesis, the formation of new blood vessels. Lopes notes that blood-vessel growth supports tissue repair but is also used by some tumors. He says this is a reason to investigate possible effects, not evidence that BPC-157 causes cancer. Human evidence is lacking, and any risks from prolonged exposure or use by people with current or previously treated cancers remain undetermined.
The 2025 Las Vegas cases also remain unresolved: investigators could not identify the exact injected products or determine what caused the severe reactions. More broadly, the available source material does not establish whether manufacturing safeguards will prevent adverse events or whether future clinical studies will show benefits for the uses promoted commercially.
FDA Rulemaking and Patient Evidence
HHS’s policy is an interim measure while the FDA considers formal rulemaking. The next regulatory milestone is the agency’s decision on how to proceed with the substances after its review. The source material does not report a decision date or say whether the FDA has announced further steps.
For patients and clinicians, the evidence questions remain specific: whether preparations consistently contain the stated ingredients, what risks they carry, and whether they improve outcomes for the conditions for which they are used. Lopes argues that clinical trials, rather than manufacturing records alone, are needed to establish safety and benefit. Until more evidence is available, the policy should not be read as an FDA finding that these peptides are approved treatments.
Key Questions
Does the HHS policy mean the FDA has approved these peptides?
No. The policy is an interim enforcement-discretion approach for compounding under specified conditions while the FDA considers formal rulemaking. It does not establish FDA approval, safety or effectiveness.
Which peptides are covered by the policy?
The six named substances are BPC-157, MOTS-c, TB-500, KPV, Semax and Epitalon. The policy applies to compounding by licensed pharmacies and physicians under specified conditions, according to the source report.
What did FDA reviewers say about the evidence?
FDA reviewers found insufficient evidence in briefing documents to support adding any of the seven substances considered. They could not establish BPC-157’s effectiveness for ulcerative colitis and cited absent or very limited human safety studies for several other substances.
Is BPC-157 known to cause cancer?
No such conclusion is established in the source material. Lopes says experimental findings involving angiogenesis raise a question for research, but there is not human evidence to claim that BPC-157 causes cancer or promotes tumor progression.
What should patients understand about the policy?
Conditions such as ingredient sourcing, identity and purity documentation, labeling and adverse-event reporting may address some product-quality concerns. They do not prove a peptide is effective or establish its overall safety for a particular use.
Source: medpagetoday.com
